NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.53
0.13 (3.82%)
▲
5d:
+9.29%
30d:
+2.92%
90d:
-27.22%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 11.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 11.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.05
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.24
43.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.53, which is considered extended relative to its 30-day fair value range of $3.26 to $3.46. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.2) compared to its historical average (17.8). Remarkably, the market is currently pricing in an annual earnings decline of 11.9% over the next few years. This pessimistic expectation contrasts with the company's recent 16.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is approaching resistance at $3.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: NAGE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.42 (+251.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is approaching resistance at $3.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: NAGE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.42 (+251.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.26 -
$3.46
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 251.7% below Wall St target ($12.42)
Trading Range Analysis
30-Day Trading Range
$3.26 -
$3.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.12
Resistance Level
$3.58
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.17
Wall Street Target
$12.42
(+251.7%)
Revenue Growth (YoY)
3.3%
Earnings Growth (YoY)
16.7%
Profit Margin
14.3%
Valuation Discount vs History
-11.9% cheaper
PE vs Historical
12.2 vs 17.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.9%
(market-implied from PE analysis)
1-Year Target
$3.18
(-10%)
2-Year Target
$2.86
(-19%)
3-Year Target
$2.57
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→18)
$3.76
(+7%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 52.6%)
$20.29
(+475%)
Base:
(SPY PE: 12.2, Growth: 52.6%)
$11.91
(+238%)
Bear:
(PE: 10.3, Growth: 52.6%)
$10.13
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 16.19 | Current EPS (TTM): $0.21
Bull Case
$5.16
(+46%)
Analyst growth 38.1%, PE expands to 17.8
Base Case
$4.70
(+33%)
Market implied 38.1%, PE stable at 16.2
Bear Case
$2.31
(-35%)
Severe decline -20.0%, PE contracts to 13.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.2 to 17.8
Stabilization Target:
$5.16
(+46.2%)
PE Expansion Potential:
+46.2%
Share & Embed Analysis
Last updated: August 04, 2026 6:36 AM ET
Data refreshes hourly during market hours. Next update: 7:36 AM
Data refreshes hourly during market hours. Next update: 7:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 56 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$207 | 58 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
